phase III trial

Sydney, Australia, September 1, 2026 Kazia Therapeutics Limited has reported new preclinical and translational findings suggesting that its investigational...

Hong Kong, Shanghai, China, and Florham Park, New Jersey, August 31, 2026 HUTCHMED (China) Limited has announced positive high-level...

CAMBRIDGE, Mass., August 5, 2026 Obsidian Therapeutics announced the enrollment of the first patient in the registration-enabling cohort of...

MIAMI, August 5, 2026 Summit Therapeutics announced the launch of the Phase II/III HARMONi-GU1 study, the company’s first global...

PORTLAND, Ore., July 29, 2026 Trace Biosciences, Inc. has secured a strategic investment from Axogen, Inc. to accelerate clinical...

CHICAGO, July 30, 2026 EVERSANA has been selected by Innovacell Inc. as its exclusive U.S. commercialization partner to support...

Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...

Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...

CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...

SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...